Skip to content
Prescott Bio Canada

NAD+: Research Summary

Published: 2026-08-03 · Last updated: 2026-08-03

Mechanism

NAD+ (nicotinamide adenine dinucleotide) is a small-molecule coenzyme, not a peptide, but is routinely grouped with peptide protocols because of its role as a co-substrate for the sirtuin family of NAD-dependent deacetylases and for PARP DNA-repair enzymes and CD38. Cellular NAD+ is consumed and regenerated continuously; net NAD+ pools decline with age in most measured human tissues. The mechanistic rationale for supplementation is to raise available NAD+ and thereby increase sirtuin and PARP activity in target tissues, with downstream effects on mitochondrial biogenesis, DNA repair, and inflammatory tone. Precursor strategies (nicotinamide riboside, NR; nicotinamide mononucleotide, NMN) and direct NAD+ administration are the two main routes studied.

Published trials

Precursor trials are the deeper evidence base. Multiple placebo-controlled RCTs of oral NR (250–1000 mg/day) have reported dose-dependent increases in whole-blood NAD+ levels within days to weeks, with favorable tolerability. NMN trials have reported similar NAD+ elevation and, in some studies, signals on aerobic capacity, walking speed in older adults, and metabolic markers. Direct intravenous NAD+ has been evaluated in small studies of substance-use recovery and neurodegeneration, mostly at open-label or small-RCT scale.

Subcutaneous NAD+ (the injectable formulation commonly used in peptide- protocol contexts) has less peer-reviewed clinical trial data than the oral precursors, though pharmacokinetic and small clinical exposure studies exist. Hard clinical-outcome trials (mortality, incident disease, functional decline) at long time horizons are not yet available for any NAD+ intervention.

Safety profile

Oral NR and NMN have favorable published tolerability profiles at studied doses; the most-reported adverse events are mild GI symptoms and flushing. Intravenous NAD+ infusions have been associated with dose-limiting reactions (chest tightness, nausea, headache) that are typically infusion-rate- dependent. Subcutaneous NAD+ can produce local injection-site reactions and, at higher doses or faster absorption, transient flushing. Theoretical oncology concerns tied to sustained sirtuin/PARP modulation are discussed in the literature but not established in human trials.

How it compares in its class

NAD+ sits within the broader "NAD-boosting" strategy class alongside NR, NMN, nicotinic acid, and sirtuin-activating polyphenols. Oral NR has the deepest RCT-grade pharmacokinetic and safety data; injectable NAD+ has thinner controlled evidence but is the fastest route to systemic NAD+ elevation. Precursor-versus-direct approaches remain an open comparative question in the literature.

References

  • PMID: 27508062 — Yoshino J et al., "NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR." Cell Metab 2018.
  • PMID: 30485349 — Rajman L et al., "Therapeutic Potential of NAD-Boosting Molecules." Cell Metab 2018.
  • PMID: 33580195 — Yoshino M et al., NMN in prediabetic women. Science 2021.
  • DOI: 10.1126/science.abe9985 — Science 2021 NMN clinical trial (Yoshino).

Buy NAD+ in Canada: Prescott Bio Canada carries NAD+ vials — HPLC + mass-spec tested, ships from Richmond BC in 2-4 business days.